Nonalcoholic Fatty Liver Disease (NAFLD/MASLD): Overview, Diagnosis, and Treatment
Nonalcoholic fatty liver disease, now increasingly called MASLD, affects roughly a third of the world's adult population according to recent meta-analyses — yet most people don't know they have it, since the disease is typically silent for years. We explain how it's diagnosed, why it progresses to more serious liver inflammation (NASH/MASH) in some patients, and why weight loss remains the first-line treatment.
Redakcja VitMode — Badania i biomarkerythe VitMode editorial team, no individual bylinesPublished13 min readAbout 13 min left
How this article was made
- Author
- Redakcja VitMode — Badania i biomarkery — the VitMode editorial team, no individual bylines
- Method
- Prepared from primary sources: clinical trials, meta-analyses and guidelines. We describe study findings separately from our interpretation.
- Source verification
- Cited PubMed papers are automatically checked for a matching identifier, title and publication year.
- Medical review
- none — this article has not been reviewed by a physician
- Last updated
The content is educational and does not replace medical advice. Read the full editorial process
Table of contents
TL;DR — key takeaways
- →A disease affecting one in three adults that rarely causes symptoms
- →From simple steatosis to NASH/MASH — a disease spectrum
- →How NAFLD/MASLD is actually diagnosed
- →Who is at risk
- →Why weight loss is the first-line treatment
- →New pharmacological options — cautious optimism
- →When NAFLD/MASLD becomes a serious problem
- →Summary table
- →Our editorial recommendation
